149 related articles for article (PubMed ID: 15200492)
1. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
Yki-Järvinen H
Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
[TBL] [Abstract][Full Text] [Related]
2. Insulin glargine (Lantus).
Owens DR; Griffiths S
Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
[TBL] [Abstract][Full Text] [Related]
3. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
Yki-Järvinen H
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
[TBL] [Abstract][Full Text] [Related]
6. Refining basal insulin therapy: what have we learned in the age of analogues?
Devries JH; Nattrass M; Pieber TR
Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
8. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
9. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
[TBL] [Abstract][Full Text] [Related]
10. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
11. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine: a long-acting insulin for diabetes mellitus.
Garces K
Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
[TBL] [Abstract][Full Text] [Related]
13. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
Rosak C; Jung R; Hofmann U
Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
Lam S
Heart Dis; 2003; 5(3):231-40. PubMed ID: 12783637
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
17. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
18. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
19. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
20. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
